Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.7223 -0.0276 (-3.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 67,668
Open 0.7350
Bid (Size) 0.7118 (500)
Ask (Size) 0.7800 (1,600)
Prev. Close 0.7499
Today's Range 0.7223 - 0.7602
52wk Range 0.6300 - 1.510
Shares Outstanding 10,134,160
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
On Friday, there are stocks with unusual volume. Let's take a look. ↗
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill

Performance

YTD
-2.1%
-2.1%
1 Month
-5.1%
-5.1%
3 Month
-23.0%
-23.0%
6 Month
-26.1%
-26.1%
1 Year
-40.3%
-40.3%

More News

Read More
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Via Chartmill
News headline image
Which stocks are most active on Thursday? ↗
Via Chartmill
News headline image
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024 ↗
Via InvestorPlace
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Gapping stocks in Thursday's session ↗
Via Chartmill
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
PMCB Stock Jumps 25% After Company Sells Stake In Femasys ↗
Via Stocktwits
News headline image
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024 ↗
Via InvestorPlace
News headline image
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
From Femasys Inc.
Via GlobeNewswire
News headline image
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
PharmaCyte Biotech Announces Final Results of Tender Offer
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
From PharmaCyte Biotech, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Via Benzinga
News headline image
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
From PharmaCyte Biotech, Inc.
Via Business Wire

Frequently Asked Questions

Is PharmaCyte Biotech, Inc. - Common Stock publicly traded?
Yes, PharmaCyte Biotech, Inc. - Common Stock is publicly traded.
What exchange does PharmaCyte Biotech, Inc. - Common Stock trade on?
PharmaCyte Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for PharmaCyte Biotech, Inc. - Common Stock?
The ticker symbol for PharmaCyte Biotech, Inc. - Common Stock is PMCB on the Nasdaq Stock Market
What is the current price of PharmaCyte Biotech, Inc. - Common Stock?
The current price of PharmaCyte Biotech, Inc. - Common Stock is 0.7223
When was PharmaCyte Biotech, Inc. - Common Stock last traded?
The last trade of PharmaCyte Biotech, Inc. - Common Stock was at 04/24/26 04:00 PM ET
What is the market capitalization of PharmaCyte Biotech, Inc. - Common Stock?
The market capitalization of PharmaCyte Biotech, Inc. - Common Stock is 7.32M
How many shares of PharmaCyte Biotech, Inc. - Common Stock are outstanding?
PharmaCyte Biotech, Inc. - Common Stock has 7M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.